Welcome to our dedicated page for Altamira Therapeutics news (Ticker: CYTOF), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics stock.
Altamira Therapeutics Ltd (CYTOF) is a clinical-stage biopharmaceutical company pioneering targeted radioligand therapies for oncology. This page serves as the definitive source for official updates and analysis on the company's progress in precision medicine.
Investors and researchers will find curated news spanning clinical trial developments, strategic partnerships, and regulatory milestones. Our coverage emphasizes Altamira's innovative approach to combining diagnostic precision with therapeutic efficacy, particularly in cancer treatment research.
Key updates include progress reports on novel therapeutic candidates, collaborations with industry leaders, and financial performance insights. All content is rigorously verified to ensure alignment with corporate disclosures and scientific publications.
Bookmark this page for streamlined access to critical updates about Altamira's advancements in radioligand technology and its expanding oncology pipeline. Regular monitoring of these developments provides valuable context for understanding the company's strategic direction in competitive biopharmaceutical markets.
Altamira Therapeutics (OTCQB: CYTOF), a company focused on RNA delivery technology development for targets beyond the liver, has scheduled its Full Year 2024 Financial Results and Business Update Call for April 30, 2025, at 8:00 am ET.
The presentation will feature prepared remarks from Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda. The call will be conducted in listen-only mode, with replay access available through the webcast link after the live event.
Altamira Therapeutics (OTCQB:CYTOF) has received a Notice of Allowance from the USPTO for a patent application (#17/466,142) covering the composition of Bentrio®, their nasal spray for allergic rhinitis treatment and prevention. The patent, with a priority date of September 8, 2020, will protect Bentrio's proprietary formulation in the USA, which represents the largest market for OTC allergic rhinitis products.
The drug-free and preservative-free nasal spray has shown significant effectiveness in relieving classic nasal symptoms of allergic rhinitis, including congestion, sneezing, itching, rhinorrhea, and ocular symptoms. The company plans to expand product availability globally through partnerships in the consumer health sector.
Altamira Therapeutics (OTCQB:CYTOF) has entered into a collaboration agreement with an unnamed radiopharmaceutical company to evaluate its RNA delivery platform for radiopharmaceutical targeting in cancer treatment. The collaboration will test RNA nanoparticles in conjunction with the partner's proprietary radiopharmaceuticals both in vitro and in vivo.
Upon successful completion of experiments, the partner will have the option to negotiate a license and supply agreement for developing and commercializing the RNA nanoparticles in cancer treatment. The global radiopharmaceutical market reached $8.4 billion in 2024 and is projected to grow to $17.1 billion by 2033.
Radiopharmaceutical therapy utilizes small amounts of radioactive compounds that, when injected, travel through the bloodstream to bind to tumor-specific receptors for diagnosis and treatment of various diseases, particularly cancer.
Altamira Therapeutics (OTCQB:CYTOF) has successfully tested its nanoparticle-based delivery platform for circular mRNA, demonstrating higher protein expression compared to linear mRNA in vitro. The company has filed a provisional patent application with the USPTO and will offer the platform under the CycloPhore™ brand, alongside existing OligoPhore™ (siRNA) and SemaPhore™ (mRNA) solutions.
The circular mRNA technology offers enhanced protein expression and greater stability compared to linear mRNA, potentially enabling lower dosing and less frequent administrations for therapeutic indications and vaccines. This development further validates the versatility of Altamira's extrahepatic RNA delivery platform.
